Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;41(1):334-339.
doi: 10.1080/0886022X.2019.1577257.

The protective effect and mechanism of rapamycin in the rat model of IgA nephropathy

Ning Guo  1 , Shengli Liu  1 , Laurine M Bow  2   3 , Xianquan Cui  1 , Luwei Zhang  1 , Shihao Xu  1 , Sai Lu  1 , Jun Tian  1
Affiliations

The protective effect and mechanism of rapamycin in the rat model of IgA nephropathy

Ning Guo et al. Ren Fail. 2019 Nov.

Abstract

Background: The pathogenesis of the development of IgA nephropathy has not been clear up to now. At present, some studies revealed that the mTOR pathway may participate in IgA nephropathy; however, the mechanism has not been systematically studied. In this study, we established an IgAN rat model to investigate the protective effects of rapamycin as a new type of immunosuppressant, as well as its therapeutic mechanisms.

Methods: After the establishment of IgA nephropathy model, rats were treated with different concentrations of rapamycin, and the protective effect of different concentrations of rapamycin on renal function of the rats was observed. The deposition of IgA was observed by immunofluorescence. The kidney expression of Akt and p70S6k proteins in mTOR pathway was examined using the western blot assay after rapamycin treatment.

Results: Morphology and immunofluorescence confirmed that the rat model of IgA nephropathy was successfully established. In particular, the level of proteinuria decreased with the increase of the dose of rapamycin, as well as the deposition of IgA in glomeruli. Moreover, the western blot analysis indicated that the expression of p70S6K in the downstream of mTOR pathway decreased and the upstream protein AKT of the mTOR pathway was overexpressed in the rats model.

Conclusion: We found that rapamycin has protective effects in the IgA nephropathy rat model in a dose-dependent manner. In addition, the result of western blot assay suggested that rapamycin may display its therapeutic effects through interfering the AKT-mTOR-p70S6K signaling pathway.

Keywords: IgA nephropathy; animal model; mTOR pathway; rapamycin.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PAS stain and immunofluorescence photograph of IgAN rats model.
Figure 2.
Figure 2.
The photograph of immunofluorescence assay after different concentrations of rapamycin treatment.
Figure 3.
Figure 3.
Expression of p70S6K and AKT after different concentrations of rapamycin treatment in the rats model (◆ showed there was no statistical significance, ◇ showed there was statistical significance and p < 0.05, ◇◇ showed there was statistical significance and p < 0.01).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402–2414. - PubMed
    1. Wada J, Sugiyama H, Makino H. Pathogenesis of IgA nephropathy. Semin Nephrol. 2003;23:556–563. - PubMed
    1. Monteiro RC, Halbwachs-Mecarelli L, Roque-Barreira MC, et al. . Charge and size of mesangial IgA in IgA nephropathy. Kidney Int. 1985; 28:666–671. - PubMed
    1. Segarra A. Progress in understanding the pathogenesis of IgA nephropathy: new perspectives for the near future? Nefrologia Publicacion Oficial De La Sociedad Espanola Nefrologia. 2010;30:501. - PubMed
    1. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253:905–909. - PubMed

MeSH terms

LinkOut - more resources